We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+47.65%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$600M
AUM Growth
+$162M
Cap. Flow
+$3.3M
Cap. Flow %
0.55%
Top 10 Hldgs %
72.6%
Holding
57
New
6
Increased
11
Reduced
18
Closed
13
Avg Time Held
6.8 quarters
Top 10 Avg Time Held
6.2 quarters
Top 20 Avg Time Held
5.9 quarters

Top Buys

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$18.3M
2
CDXS icon
Codexis
CDXS
+$16.4M
3
LQDA icon
Liquidia Corp
LQDA
+$15M
4
DNA icon
Ginkgo Bioworks
DNA
+$8.22M
5
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$3.51M

Top Sells

Rank Stock Value
1
CPRX icon
Catalyst Pharmaceutical
CPRX
+$9.78M
2
FDMT icon
4D Molecular Therapeutics
FDMT
+$7.26M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.19M
4
CYTK icon
Cytokinetics
CYTK
+$6.87M
5
NTLA icon
Intellia Therapeutics
NTLA
+$4.88M

Sector Composition

Rank Sector Weight
1 Healthcare 98.64%
2 Miscellaneous 1.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HROW icon
1
Harrow
HROW
$1.07B
$179M 29.92%
3,990,000
– –
2018 Q3
24 quarters
TGTX icon
2
TG Therapeutics
TGTX
$8.25B
$53.3M 8.89%
2,280,000
– –
2023 Q3
4 quarters
OCUL icon
3
Ocular Therapeutix
OCUL
$1.65B
$43.7M 7.29%
5,025,000
-282,500
-5% -$2.33M
2019 Q1
22 quarters
ARVN icon
4
Arvinas
ARVN
$473M
$30.9M 5.16%
1,255,000
+700,000
+126% +$18.3M
2023 Q4
3 quarters
CDXS icon
5
Codexis
CDXS
$151M
$27M 4.51%
8,770,000
+5,315,000
+154% +$16.4M
2014 Q1
42 quarters
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$6.04B
$26.2M 4.37%
500,000
-15,000
-3% -$719K
2022 Q2
9 quarters
KROS icon
7
Keros Therapeutics
KROS
$225M
$23M 3.83%
395,276
+27,776
+8% +$1.37M
2021 Q1
14 quarters
IMNM icon
8
Immunome
IMNM
$2.09B
$18.1M 3.02%
1,237,500
+135,000
+12% +$1.92M
2024 Q2
1 quarter
LQDA icon
9
Liquidia Corp
LQDA
$2.35B
$17M 2.83%
1,698,142
+1,373,142
+423% +$15M
2021 Q4
11 quarters
ETON icon
10
Eton Pharmaceutcials
ETON
$1.57B
$16.7M 2.78%
2,780,000
+385,000
+16% +$1.63M
2018 Q4
23 quarters
EWTX icon
11
Edgewise Therapeutics
EWTX
$4.07B
$13.9M 2.33%
522,500
-57,500
-10% -$1.14M
2022 Q1
10 quarters
CRGX icon
12
DELISTED
CARGO Therapeutics
CRGX
$11.8M 1.97%
541,437
-14,263
-3% -$255K
2024 Q2
1 quarter
APLT icon
13
DELISTED
Applied Therapeutics
APLT
$11.2M 1.87%
1,320,000
-360,000
-21% -$2.12M
2023 Q3
4 quarters
PCVX icon
14
Vaxcyte
PCVX
$10.7B
$9.71M 1.62%
85,000
– –
2020 Q3
16 quarters
NRIX icon
15
Nurix Therapeutics
NRIX
$2.33B
$9.44M 1.57%
420,000
+1,072
+0.3% +$24.3K
2024 Q1
2 quarters
SLRN icon
16
DELISTED
ACELYRIN
SLRN
$9.34M 1.56%
1,893,660
+313,660
+20% +$1.62M
2023 Q2
5 quarters
TRVI icon
17
Trevi Therapeutics
TRVI
$1.78B
$8.58M 1.43%
2,567,990
-77,010
-3% -$229K
2022 Q4
7 quarters
BDSX icon
18
Biodesix
BDSX
$265M
$6.97M 1.16%
190,750
-10,250
-5% -$353K
2023 Q3
4 quarters
DNA icon
19
Ginkgo Bioworks
DNA
$818M
$6.68M 1.11%
+820,202
New +$8.22M
2024 Q3
0 quarters
JSPR icon
20
Jasper Therapeutics
JSPR
$17M
$6.65M 1.11%
353,500
-38,500
-10% -$767K
2023 Q4
3 quarters
XOMA icon
21
DELISTED
Xoma
XOMA
$6.62M 1.1%
250,000
– –
2017 Q1
30 quarters
NUVL icon
22
DELISTED
Nuvalent
NUVL
$6.55M 1.09%
64,000
+4,700
+8% +$390K
2024 Q2
1 quarter
NAMS icon
23
NewAmsterdam Pharma
NAMS
$2.49B
$5.56M 0.93%
335,000
+20,000
+6% +$346K
2023 Q4
3 quarters
URGN icon
24
UroGen Pharma
URGN
$1.85B
$5.13M 0.86%
404,100
-7,900
-2% -$117K
2022 Q2
9 quarters
PTGX icon
25
Protagonist Therapeutics
PTGX
$9.12B
$4.72M 0.79%
105,000
– –
2023 Q4
3 quarters
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2024 Portfolio in Review

As of Q3 2024, Opaleye Management held 57 positions worth $600M, up 37% from $438M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Opaleye Management's Q3 2024 filing shows 6 new, 11 increased, 18 reduced and 13 closed positions. Its largest new stake was Ginkgo Bioworks: 820,202 shares worth $6.68M. The largest sale was Catalyst Pharmaceutical, an estimated $9.78M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q3 2024 buy was Ginkgo Bioworks: 820,202 shares worth $6.68M.
  • Opaleye Management added most to Arvinas in Q3 2024, an estimated $18.3M increase.
  • Opaleye Management's biggest Q3 2024 reduction was Catalyst Pharmaceutical, cutting an estimated $9.78M.
  • Opaleye Management fully exited 4D Molecular Therapeutics in Q3 2024, selling an estimated $7.26M.
  • Opaleye Management's ten largest holdings make up 73% of its $600M portfolio in Q3 2024.
  • Opaleye Management opened 6 new positions and closed 13 in Q3 2024.
  • Opaleye Management's portfolio value rose 37% quarter-over-quarter to $600M.

Based on Opaleye Management's 13F filing for Q3 2024, filed 14 Nov 2024.